

Ref. No: 0667
Date: 07/02/24
Subject: Medications (Ophthalmology)

REQUEST

1. For the 4 months from September to December 2023, how many patients received the following intra-vitreous treatments for any eye condition:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Faricimab
- Ranibizumab - Lucentis
- Ranibizumab - Ongavia

2. For the patients above, how many were new to intra-vitreous treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Faricimab
- Ranibizumab - Lucentis
- Ranibizumab - Ongavia

RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1st July 2023, as such parts of the response may be provided in two sections relating to the hospital sites of each of the legacy organisations.

1. For the 4 months from September to December 2023, how many patients received the following intra-vitreous treatments for any eye condition:

St Helens and Knowsley:

Treatment	No. Patients
Aflibercept	704
Bevacizumab	0

Brolucizumab	<5
Dexamethasone	37
Faricimab	234
Ranibizumab - Lucentis	315
Ranibizumab - Ongavia	184

Section 40: personal information

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances Section 40(2) and Section 40(3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle which states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure, and in such circumstances, Section 40 confers an absolute exemption on disclosure.

Southport and Ormskirk:

Nil

2. **For the patients above, how many were new to intra-vitreous treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.**

St Helens and Knowsley:

Treatment	No. Patients
Aflibercept	200
Bevacizumab	0
Brolucizumab	0
Dexamethasone	7
Faricimab	57
Ranibizumab - Lucentis	21
Ranibizumab - Ongavia	10

Southport and Ormskirk:

Nil